Cargando…
Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations
Background and Objectives: During the coronavirus disease 2019 (COVID-19) outbreak, the European Association of Urology (EAU) Guidelines Office Rapid Reaction Group (GORRG) recommended that patients with clinical stage I (CSI) seminoma be offered active surveillance (AS). This meta-analysis aimed to...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692719/ https://www.ncbi.nlm.nih.gov/pubmed/36363471 http://dx.doi.org/10.3390/medicina58111514 |
_version_ | 1784837338956824576 |
---|---|
author | Kang, Dong Hyuk Cho, Kang Su Jeong, Jae Yong Moon, Young Joon Chung, Doo Yong Jung, Hae Do Lee, Joo Yong |
author_facet | Kang, Dong Hyuk Cho, Kang Su Jeong, Jae Yong Moon, Young Joon Chung, Doo Yong Jung, Hae Do Lee, Joo Yong |
author_sort | Kang, Dong Hyuk |
collection | PubMed |
description | Background and Objectives: During the coronavirus disease 2019 (COVID-19) outbreak, the European Association of Urology (EAU) Guidelines Office Rapid Reaction Group (GORRG) recommended that patients with clinical stage I (CSI) seminoma be offered active surveillance (AS). This meta-analysis aimed to evaluate the efficacy of AS versus adjuvant treatment with chemotherapy or radiotherapy for improving the overall survival (OS) of CSI seminoma patients. Materials and Methods: A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed/Medline, EMBASE, and Cochrane Library databases were searched. The primary outcome was 5-year OS, and the secondary outcome was the 5-year relapse-free survival (RFS). The outcomes were analyzed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 14 studies were included. Overall, the quality scores were relatively high, and little publication bias was noted. In terms of the 5-year OS, 7 studies were analyzed; there was no significant difference between AS and adjuvant treatment (OR, 0.99; 95% CI, 0.41–2.39; p = 0.97). In terms of 5-year RFS, 12 studies were analyzed. Adjuvant treatment reduced the risk of 5-year recurrence by 85% compared with AS (OR, 0.15; 95% CI, 0.08–0.26; p < 0.001). Conclusions: In terms of the OS in CSI seminoma patients, no intergroup difference was noted, so it is reasonable to offer AS, as recommended by the EAU GORRG until the end of the COVID-19 pandemic. However, since there is a large intergroup difference in the recurrence rate, further research on the long-term (>5 years) outcomes is warranted. |
format | Online Article Text |
id | pubmed-9692719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96927192022-11-26 Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations Kang, Dong Hyuk Cho, Kang Su Jeong, Jae Yong Moon, Young Joon Chung, Doo Yong Jung, Hae Do Lee, Joo Yong Medicina (Kaunas) Systematic Review Background and Objectives: During the coronavirus disease 2019 (COVID-19) outbreak, the European Association of Urology (EAU) Guidelines Office Rapid Reaction Group (GORRG) recommended that patients with clinical stage I (CSI) seminoma be offered active surveillance (AS). This meta-analysis aimed to evaluate the efficacy of AS versus adjuvant treatment with chemotherapy or radiotherapy for improving the overall survival (OS) of CSI seminoma patients. Materials and Methods: A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed/Medline, EMBASE, and Cochrane Library databases were searched. The primary outcome was 5-year OS, and the secondary outcome was the 5-year relapse-free survival (RFS). The outcomes were analyzed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 14 studies were included. Overall, the quality scores were relatively high, and little publication bias was noted. In terms of the 5-year OS, 7 studies were analyzed; there was no significant difference between AS and adjuvant treatment (OR, 0.99; 95% CI, 0.41–2.39; p = 0.97). In terms of 5-year RFS, 12 studies were analyzed. Adjuvant treatment reduced the risk of 5-year recurrence by 85% compared with AS (OR, 0.15; 95% CI, 0.08–0.26; p < 0.001). Conclusions: In terms of the OS in CSI seminoma patients, no intergroup difference was noted, so it is reasonable to offer AS, as recommended by the EAU GORRG until the end of the COVID-19 pandemic. However, since there is a large intergroup difference in the recurrence rate, further research on the long-term (>5 years) outcomes is warranted. MDPI 2022-10-24 /pmc/articles/PMC9692719/ /pubmed/36363471 http://dx.doi.org/10.3390/medicina58111514 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Kang, Dong Hyuk Cho, Kang Su Jeong, Jae Yong Moon, Young Joon Chung, Doo Yong Jung, Hae Do Lee, Joo Yong Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title | Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title_full | Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title_fullStr | Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title_full_unstemmed | Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title_short | Surveillance versus Adjuvant Treatment with Chemotherapy or Radiotherapy for Stage I Seminoma: A Systematic Review and Meta-Analysis According to EAU COVID-19 Recommendations |
title_sort | surveillance versus adjuvant treatment with chemotherapy or radiotherapy for stage i seminoma: a systematic review and meta-analysis according to eau covid-19 recommendations |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692719/ https://www.ncbi.nlm.nih.gov/pubmed/36363471 http://dx.doi.org/10.3390/medicina58111514 |
work_keys_str_mv | AT kangdonghyuk surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT chokangsu surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT jeongjaeyong surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT moonyoungjoon surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT chungdooyong surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT junghaedo surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations AT leejooyong surveillanceversusadjuvanttreatmentwithchemotherapyorradiotherapyforstageiseminomaasystematicreviewandmetaanalysisaccordingtoeaucovid19recommendations |